AGFG1 and Miyoshi myopathy: Tumor/TV was markedly reduced in Ki26894-treated mice (Figure 7D), which is consistent with the serum levels of soluble human IL-6R, a surrogate marker for a human MM tumor burden, in MM-bearing SCID-rab mice.